Covagen ^Companies

Covagen is an organization that specializes in developing protein-based therapeutics for the treatment of inflammatory diseases and cancer. They achieve this by fusing their human Fynomer binding proteins to antibodies, resulting in bispecific FynomAbs with novel modes of action and enhanced efficacy. Their goal is to access novel biology for each product candidate, and their lead FynomAb COVA322 is being developed for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. Covagen was founded in 2007 as a spin-off company from ETH Zurich and has received support from a strong syndicate of investors including Novartis Venture Fund, Edmond de Rothschild Investment Partners, and Baxter Ventures.